Adlai Nortye (ANL) Competitors $2.63 +0.02 (+0.77%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends ANL vs. CTNM, AMLX, FDMT, VALN, KMDA, ACIU, JSPR, KOD, CYRX, and BTMDShould you be buying Adlai Nortye stock or one of its competitors? The main competitors of Adlai Nortye include Contineum Therapeutics (CTNM), Amylyx Pharmaceuticals (AMLX), 4D Molecular Therapeutics (FDMT), Valneva (VALN), Kamada (KMDA), AC Immune (ACIU), Jasper Therapeutics (JSPR), Kodiak Sciences (KOD), Cryoport (CYRX), and biote (BTMD). These companies are all part of the "pharmaceutical products" industry. Adlai Nortye vs. Contineum Therapeutics Amylyx Pharmaceuticals 4D Molecular Therapeutics Valneva Kamada AC Immune Jasper Therapeutics Kodiak Sciences Cryoport biote Adlai Nortye (NASDAQ:ANL) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, community ranking, media sentiment, analyst recommendations, profitability and dividends. Do analysts rate ANL or CTNM? Adlai Nortye presently has a consensus target price of $9.00, suggesting a potential upside of 242.21%. Contineum Therapeutics has a consensus target price of $29.25, suggesting a potential upside of 107.59%. Given Adlai Nortye's higher possible upside, equities research analysts plainly believe Adlai Nortye is more favorable than Contineum Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adlai Nortye 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Contineum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Which has stronger earnings & valuation, ANL or CTNM? Contineum Therapeutics has higher revenue and earnings than Adlai Nortye. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdlai Nortye$5M19.41-$104.87MN/AN/AContineum Therapeutics$50M7.26$22.72MN/AN/A Does the MarketBeat Community prefer ANL or CTNM? Adlai Nortye received 1 more outperform votes than Contineum Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformAdlai NortyeOutperform Votes8100.00% Underperform VotesNo VotesContineum TherapeuticsOutperform Votes7100.00% Underperform VotesNo Votes Do institutionals & insiders have more ownership in ANL or CTNM? 35.2% of Adlai Nortye shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media prefer ANL or CTNM? In the previous week, Contineum Therapeutics had 2 more articles in the media than Adlai Nortye. MarketBeat recorded 2 mentions for Contineum Therapeutics and 0 mentions for Adlai Nortye. Contineum Therapeutics' average media sentiment score of 0.07 beat Adlai Nortye's score of 0.00 indicating that Contineum Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Adlai Nortye Neutral Contineum Therapeutics Neutral Is ANL or CTNM more profitable? Adlai Nortye's return on equity of 0.00% beat Contineum Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Adlai NortyeN/A N/A N/A Contineum Therapeutics N/A -49.92%-20.52% SummaryContineum Therapeutics beats Adlai Nortye on 7 of the 13 factors compared between the two stocks. Ad Brownstone ResearchMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.Click here and I’ll tell you everything you need to know. Get Adlai Nortye News Delivered to You Automatically Sign up to receive the latest news and ratings for ANL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANL vs. The Competition Export to ExcelMetricAdlai NortyePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$97.05M$6.59B$5.20B$8.85BDividend YieldN/A8.14%5.53%4.08%P/E RatioN/A6.3179.4715.17Price / Sales19.41357.041,246.7687.28Price / CashN/A53.8240.9036.92Price / BookN/A10.617.196.55Net Income-$104.87M$153.27M$119.54M$226.22M7 Day Performance-15.71%3.97%2.12%3.77%1 Month Performance31.50%-6.72%-2.43%4.64%1 Year Performance-74.19%33.26%34.52%29.21% Adlai Nortye Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANLAdlai Nortye2.2772 of 5 stars$2.63+0.8%$9.00+242.2%-74.2%$97.05M$5M0.00127Gap UpCTNMContineum Therapeutics1.6522 of 5 stars$14.09-1.7%$29.25+107.6%N/A$363.21M$50M0.0031AMLXAmylyx Pharmaceuticals4.1971 of 5 stars$5.27+1.5%$11.43+116.9%-58.5%$361.26M$380.79M-1.37200Gap UpFDMT4D Molecular Therapeutics3.0152 of 5 stars$7.79-2.5%$42.13+440.8%-35.7%$360.13M$20.72M-2.73201Analyst ForecastNews CoverageVALNValneva2.3311 of 5 stars$4.43+0.2%$18.50+317.6%-63.3%$359.94M$165.52M-34.08700KMDAKamada3.7856 of 5 stars$5.87+0.3%$14.50+147.0%+23.6%$337.41M$142.52M20.96360ACIUAC Immune2.3365 of 5 stars$3.38+2.7%$12.00+255.0%+11.9%$334.42M$40.97M-7.15140Positive NewsJSPRJasper Therapeutics2.4982 of 5 stars$22.05+1.0%$74.86+239.5%+254.2%$330.75MN/A-4.6620KODKodiak Sciences3.0115 of 5 stars$6.19+4.9%$3.50-43.5%+157.9%$325.72MN/A-1.7090CYRXCryoport2.8715 of 5 stars$6.56+0.6%$12.50+90.5%-53.2%$324.27M$226.11M-1.941,170Insider TradeBTMDbiote3.0299 of 5 stars$5.98-2.6%$8.39+40.3%+15.9%$324.24M$185.36M23.62194 Related Companies and Tools Related Companies Contineum Therapeutics Alternatives Amylyx Pharmaceuticals Alternatives 4D Molecular Therapeutics Alternatives Valneva Alternatives Kamada Alternatives AC Immune Alternatives Jasper Therapeutics Alternatives Kodiak Sciences Alternatives Cryoport Alternatives biote Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ANL) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adlai Nortye Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adlai Nortye With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
